A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from a Phase 2a part of clinical trial. The open-label study (NCT03815942), called ADVANCE, may still be recruiting up to 36 patients in the U.K. It is sponsored and being conducted by the University of Oxford, and is co-funded by Vaccitech and the FP7 programme of the European Commission. The trial’s main goal is to assess the safety and efficacy of VTP-800 when used in combination with Bristol-Myers Squibb‘s Opdivo at reducing blood levels of prostate-specific antigen (PSA) in men with intermediate risk or advanced prostate cancer. VTP-800 is a potential anti-cancer vaccine designed to prime…
April 18, 2020April 18, 2020